Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Actrapid® (insulin human rDNA).

Actrapid® (insulin human rDNA)   SmPC
Actrapid® vial®   PIL


Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Fiasp®   (insulin aspart).

Fiasp® (insulin aspart)    
Fiasp® FlexTouch®   GB SmPC NI SmPC PIL
Fiasp® Penfill®   GB SmPC NI SmPC PIL
Fiasp® vial   GB SmPC NI SmPC PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Insulatard® (insulin human rDNA).

Insulatard® (insulin human rDNA)

 

SmPC

Insulatard® InnoLet®

 

PIL

Insulatard® Penfill®

 

PIL

Insulatard® vial

 

PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Levemir® (insulin detemir).

Levemir® (insulin detemir)

  

 

Levemir® FlexPen®

  

GB SmPC NI SmPC PIL

Levemir® InnoLet®

 

GB SmPC NI SmPC PIL

Levemir® Penfill®

 

GB SmPC NI SmPC PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for NovoMix®30 (biphasic insulin aspart).

NovoMix®30 (biphasic insulin aspart)

 

SmPC

NovoMix®30 FlexPen®

 

PIL

NovoMix®30 Penfill®

  

PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for NovoRapid® (insulin aspart).

NovoRapid® (insulin aspart)

 

SmPC

NovoRapid® FlexTouch®

  

PIL

NovoRapid® FlexPen®

  

PIL

NovoRapid® Penfill®

 

PIL

NovoRapid® PumpCart®

  

PIL

NovoRapid® vial

 

PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Ozempic®  (semaglutide).

Ozempic®  (semaglutide)   SmPC
Ozempic®  0.25mg   PIL
Ozempic®  0.5mg   PIL
Ozempic®  1mg   PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Rybelsus®  (semaglutide tablets).

Rybelsus®   (semaglutide tablets)   SmPC
Rybelsus®  3mg tablet   PIL
Rybelsus®  7 mg tablet   PIL
Rybelsus®  14 mg tablet   PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Tresiba® (insulin degludec).

Tresiba® (insulin degludec)

 

GB SmPC NI SmPC

Tresiba® U100 FlexTouch®

  

PIL

Tresiba® U200 FlexTouch®

 

PIL

Tresiba®  U100 Penfill®

 

PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Victoza® (liraglutide).

Victoza® (liraglutide)   SmPC
Victoza® 2 x 3ml pen   PIL
Victoza® 3 x 3ml pen   PIL

Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for Xultophy® (insulin degludec/liraglutide).

Xultophy®  (insulin degludec/liraglutide)   SmPC
Xultophy®  3 x 3 100 u/mL pre-filled dial-a-dose pen   PIL

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.  

Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573).  Calls may be monitored for training purposes.

 This medicine is subject to additional safety monitoring.  This will allow quick identification of new safety information.  You can help by reporting any side effects you may get.  See https://yellowcard.mhra.gov.uk/ for how to report side effects.

This page is intended for members of the UK public